Advertisement
Advertisement
NVCT
Nuvectis Pharma, Inc. Common Stock
19.41
USDSponsored
+0.54
+2.83%
Aug 11, 16:00 UTC -4
Closed
Pre-Market
19.38
-0.03
-0.15%
NVCT Earnings Reports
Positive Surprise Ratio
NVCT beat 6 of 18 last estimates.
33%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.26
Implied change from Q2 26 (Revenue/ EPS)
--
/-13.33%
Implied change from Q3 25 (Revenue/ EPS)
--
/-21.21%
Nuvectis Pharma, Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, NVCT reported earnings of -0.30 USD per share (EPS) for Q2 26, missing the estimate of -0.26 USD, resulting in a -12.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.94% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.26 USD, with revenue projected to reach -- USD, implying an decrease of -13.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Seer, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.31
Surprise
-12.56%
Liquidia Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
$0.75
Actual
$0.74
Surprise
-2.34%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
FAQ
What were Nuvectis Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Nuvectis Pharma, Inc. Common Stock reported EPS of -$0.30, missing estimates by -12.28%, and revenue of $0.00, 0% as expectations.
How did the market react to Nuvectis Pharma, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -6.94%, changed from $21.60 before the earnings release to $20.10 the day after.
When is Nuvectis Pharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Nuvectis Pharma, Inc. Common Stock's next earnings report?
Based on --
analysts, Nuvectis Pharma, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement